Literature DB >> 33733344

Comparison of the three-level and the five-level versions of the EQ-5D.

Anne Simone Juhl Christiansen1, Marie Louise Sletskov Møller1, Christian Kronborg2, Ketil Jørgen Haugan3, Lars Køber4,5, Søren Højberg6, Axel Brandes7,8, Claus Graff9, Søren Zöga Diederichsen4, Jonas Bille Nielsen10,11,12, Derk Krieger13,14, Anders Gaarsdal Holst10, Jesper Hastrup Svendsen4,5,10.   

Abstract

EQ-5D is a generic instrument to measure health-related quality of life. In 2009, a new version, EQ-5D-5L, was introduced as an attempt to reduce ceiling effects and improve sensitivity to small changes over time. The objective of this study was to assess the measurement properties of the EQ-5D-5L instrument compared to the EQ-5D-3L instrument in an elderly general population with a moderate to a high degree of comorbidity. A subgroup of participants in a large clinical trial completed the EQ-5D-3L and the EQ-5D-5L questionnaires. Based on the collected data, we tested for feasibility and ceiling and floor effects. Furthermore, we assessed the redistribution properties of the responses and examined the level of inconsistency, informativity, and convergent validity. A total of 1002 persons diagnosed with hypertension, diabetes, heart failure, and/or previous stroke completed both the EQ-5D-3L and the EQ-5D-5L questionnaires. The overall ceiling effect decreased from 46% with the EQ-5D-3L to 30% with the EQ-5D-5L and absolute and relative informativity were higher for EQ-5D-5L, and there was a stronger correlation between EQ-5D-5L and EQ VAS. The EQ-5D-5L seemed to perform better than the EQ-5D-3L in terms of feasibility, ceiling effect, discriminatory power, and convergent validity. The overall ceiling effect was higher than that found in patient samples in previous studies but lower than the one found in population studies.

Entities:  

Keywords:  EQ-5D-3L; EQ-5D-5L; Health-related quality of life; Measurement properties

Year:  2021        PMID: 33733344     DOI: 10.1007/s10198-021-01279-z

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  11 in total

1.  Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada.

Authors:  J A Johnson; A S Pickard
Journal:  Med Care       Date:  2000-01       Impact factor: 2.983

Review 2.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

3.  Comparing the standard EQ-5D three-level system with a five-level version.

Authors:  Mathieu F Janssen; Erwin Birnie; Juanita A Haagsma; Gouke J Bonsel
Journal:  Value Health       Date:  2008 Mar-Apr       Impact factor: 5.725

4.  Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.

Authors:  Fanni Rencz; Peter L Lakatos; László Gulácsi; Valentin Brodszky; Zsuzsanna Kürti; Szilvia Lovas; János Banai; László Herszényi; Tamás Cserni; Tamás Molnár; Márta Péntek; Károly Palatka
Journal:  Qual Life Res       Date:  2018-09-17       Impact factor: 4.147

5.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Authors:  Ben van Hout; M F Janssen; You-Shan Feng; Thomas Kohlmann; Jan Busschbach; Dominik Golicki; Andrew Lloyd; Luciana Scalone; Paul Kind; A Simon Pickard
Journal:  Value Health       Date:  2012-05-24       Impact factor: 5.725

6.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.

Authors:  Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek
Journal:  Qual Life Res       Date:  2017-09-05       Impact factor: 4.147

7.  Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.

Authors:  Søren Zöga Diederichsen; Ketil Jørgen Haugan; Lars Køber; Søren Højberg; Axel Brandes; Christian Kronborg; Claus Graff; Anders Gaarsdal Holst; Jonas Bille Nielsen; Derk Krieger; Jesper Hastrup Svendsen
Journal:  Am Heart J       Date:  2017-02-20       Impact factor: 4.749

8.  Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.

Authors:  Luciana Scalone; Roberta Ciampichini; Stefano Fagiuoli; Ivan Gardini; Francesco Fusco; Laura Gaeta; Anna Del Prete; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Qual Life Res       Date:  2012-11-29       Impact factor: 4.147

9.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

10.  A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D.

Authors:  Ines Buchholz; Mathieu F Janssen; Thomas Kohlmann; You-Shan Feng
Journal:  Pharmacoeconomics       Date:  2018-06       Impact factor: 4.981

View more
  6 in total

1.  Feasibility properties of the EQ-5D-3L and 5L in the general population: evidence from the GP Patient Survey on the impact of age.

Authors:  Ole Marten; Wolfgang Greiner
Journal:  Health Econ Rev       Date:  2022-05-20

2.  Comparison of EQ-5D-3L and 5L versions following operative fixation of closed ankle fractures.

Authors:  Andrew Garratt; Knut Stavem
Journal:  Qual Life Res       Date:  2022-02-19       Impact factor: 3.440

3.  Virtual visits to optimize research trial offerings to heart failure patients.

Authors:  Laurie Ann Moennich; Barbara Bittel; Jerry D Estep
Journal:  Cardiovasc Digit Health J       Date:  2021-11-18

4.  Physiotherapist or physician as primary assessor for patients with suspected knee osteoarthritis in primary care - a cost-effectiveness analysis of a pragmatic trial.

Authors:  Chan-Mei Ho-Henriksson; Mikael Svensson; Carina A Thorstensson; Lena Nordeman
Journal:  BMC Musculoskelet Disord       Date:  2022-03-17       Impact factor: 2.362

5.  Feasibility and validity of the EQ-5D-3L in the elderly Europeans: a secondary data analysis using SHARE(d) data.

Authors:  Ines Buchholz; Ole Marten; Mathieu F Janssen
Journal:  Qual Life Res       Date:  2022-05-27       Impact factor: 3.440

6.  Evaluation of the EQ-5D-3L and 5L versions in low back pain patients.

Authors:  A M Garratt; H Furunes; C Hellum; T Solberg; J I Brox; K Storheim; L G Johnsen
Journal:  Health Qual Life Outcomes       Date:  2021-05-28       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.